What Shitan Treats: Main Uses and Benefits

Shitan is commonly used to help with symptoms related to viscid, sticky phlegm that resists mobilization and contributes to an ineffective cough. The medication is applied across domains where additional symptomatic support is needed for respiratory tract disorders. The medication supports the body's natural processes by thinning these secretions. This may assist with maintaining functional stability by helping to facilitate more manageable mucus expulsion and contributing to improved comfort.

The medicine is generally applied in the symptomatic treatment of various conditions, including acute bronchitis, the common cold, and chronic diagnoses like COPD or chronic bronchitis, where thick mucus is involved. This use is often applied during phases when symptoms become more noticeable, providing supportive relief that may help patients cope more steadily and assist with maintaining functional stability.

In clinical practice, Shitan may be utilized as an adjunct to other treatments when the presence of thick secretions complicates the management of respiratory tract infections.

Quick Fact: Relief for Congestion
Primary Symptom Targeted	Difficulty in clearing thick, tenacious mucus from the chest.
Typical Use Context	Symptomatic management during acute or chronic respiratory episodes.
Patient Benefit	Supports easier expectoration and may assist with managing the feeling of chest obstruction.

Regulatory References

1. European Medicines Agency (EMA) review

Eligibility Map: Who can and cannot use Shitan — official regulatory information

Eligibility scope

Populations for whom use is allowed (as stated in label): No official regulatory documentation for “Shitan” was found in the governmental sources searched (FDA, EMA). Populations for whom use is contraindicated: No official regulatory documentation for “Shitan” was found in the governmental sources searched (FDA, EMA).

---

Eligibility classifications (high-level)

Regulatory basis (EMA / FDA / etc.): Not documented in official regulatory sources searched.

---

Resulting eligibility structure

Official Eligibility Statements

• Use of “Shitan” is not supported by public, official drug labeling (Prescribing Information or Summary of Product Characteristics) from major regulatory agencies. The populations for whom this medicine is intended, as well as the groups who must strictly avoid it, are not documented in these sources.
• Standard medical practice dictates that a medicine’s use is guided by its official label, which contains details on age, physiological status (such as pregnancy or lactation), and specific health conditions (like severe hepatic or renal impairment) that would necessitate a restriction or contraindication.

---

Connection to the overall eligibility profile

The regulatory profile defining who can and cannot use Shitan cannot be formally established from the authoritative drug labeling documents provided by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This absence of a public, fact-checked eligibility statement means there are no formal, documented contraindications, use restrictions, or established age-related rules for the medicine in these official contexts.

Interactions with other medicines and products

The official interaction profile for Shitan (Bromhexine hydrochloride) is characterized by specific documented substance restrictions and pharmacokinetic patterns, as established in government regulatory prescribing information. Major regulatory documents generally note that there are no clinically relevant unfavorable interactions reported with most medicines.

Documented Interaction Patterns

Interaction Category	Specific Substance or Condition	Regulatory Constraint or Outcome
Pharmacodynamic Restriction	Cough Suppressants (Antitussives)	Non-concomitant administration is advised; combination may lead to a documented risk of retained secretions (mucus build-up).
Tissue Exposure Enhancement	Amoxicillin, Erythromycin, Oxytetracycline	Co-administration is documented to increase the concentration of these antibiotics in the sputum and bronchopulmonary secretions.

Substance and Condition-Based Alterations

The official profile includes restrictions involving non-medicinal substances and cautions related to specific physiological conditions that alter the medicine's disposition:

• Food: Administration with food is documented to increase the bioavailability of the active substance.
• Alcohol: Avoidance is advised due to the potential to increase drowsiness.
• Population-Specific Caution: The clearance of the active substance or its metabolites may be reduced in individuals with documented severe hepatic impairment or severe renal impairment.

No absolute contraindications or mandatory time-based dose separation requirements (e.g., must be separated by X hours) are explicitly stated in the single-ingredient regulatory labeling.

How Shitan Works

The action of Shitan (Bromhexine) is defined by two complementary mechanistic domains that modify the physical state and transport dynamics of respiratory secretions, contributing to a restoration of function within the mucociliary clearance pathway.

Secretolytic Action: Depolymerizing Thick Mucus

Shitan acts as a depolymerizing agent that targets the molecular structure of tenacious mucus. This action promotes the release of lysosomal hydrolytic enzymes within bronchial glandular cells. These enzymes chemically cleave the long, complex acid mucopolysaccharide fibers that contribute to abnormal viscosity and elasticity, resulting in a reduction of sputum tenacity.

Secretomotoric and Transport Enhancement

The second domain covers the processes that influence physical movement. Shitan stimulates the serous glands to increase the output of a thin, watery fluid, which dilutes the mucus and adjusts the fluid layer supporting the ciliated epithelium. By simultaneously enhancing the ciliary beat frequency, the drug increases the propulsion of the now-liquefied secretions, thereby modulating the mucociliary transport rate.

How to Use Shitan

Shitan (bromhexine hydrochloride) administration is governed by standardized guidelines defining the route, dosage ranges, and duration of use. The medication is generally administered through the oral route, available as immediate-release tablets or an oral liquid/syrup.

Official Dosing and Frequency

Administration follows a divided daily dosing regimen and is typically indicated for short-term use. Standard use protocols establish the following general principles:

• Standard Adult Dose: Usually 8 mg per dose, taken three times daily (t.i.d.).
• Initial Period: Dosing may be increased to 16 mg per dose for the first seven days of treatment to maximize the initial effect.
• Duration: Treatment should generally not exceed seven consecutive days unless otherwise advised.

Administration Details and Population Constraints

The medicine may be taken with or without food, although concomitant food intake has been noted to increase plasma concentrations. For the liquid formulation, accurate measurement is required using the dosing device provided.

Specific guidelines address vulnerable populations:

• Pediatric Use: Doses are lower for children, with administration to children under two years of age strictly requiring medical supervision.
• Hepatic/Renal Impairment: Caution is necessary, and dose adjustments may be required in cases of severe liver or kidney impairment due to potential reduced clearance of the substance.

If a dose is missed, instructions indicate that the individual should not take a double dose to compensate, but should instead continue with the next regularly scheduled dose.

Recent Clinical Evidence for HMG-CoA Reductase Inhibitors (Statins)

Extensive clinical research, including large-scale randomized controlled trials, provides compelling evidence for the efficacy and safety of HMG-CoA reductase inhibitors (commonly known as statins). These agents are primarily used to lower low-density lipoprotein cholesterol (LDL-C), a major risk factor for cardiovascular disease.

Cardiovascular Outcomes

Studies have consistently demonstrated that statin therapy significantly reduces the risk of major atherosclerotic cardiovascular events, including nonfatal myocardial infarction (heart attack), stroke, and the need for coronary revascularization procedures. This benefit is observed across various patient populations, including those with established cardiovascular disease (for secondary prevention) and those with elevated risk factors but no history of events (for primary prevention).

Safety Profile and Adverse Effects

Statins are generally well-tolerated. However, potential adverse effects have been thoroughly investigated:

Adverse Event	Clinical Trial Evidence
Muscle Symptoms	Most muscle-related symptoms (myalgia) are mild; severe injury like rhabdomyolysis is rare, occurring in less than 0.1% of patients.
New-Onset Diabetes	A small, dose-dependent increased risk is noted, primarily in patients already at high risk. The cardiovascular benefits typically outweigh this risk.
Liver Enzymes	Transient, dose-related elevations in liver enzymes are possible but clinically significant hepatotoxicity is uncommon.

For patients with a high risk of heart disease, the collective evidence supports the overall cardioprotective benefits of statin therapy. Decisions regarding initiation or continuation of therapy should be made after a comprehensive risk-benefit assessment with a healthcare provider.

Common questions about Shitan (FAQ)

Q: Are there any long-term effects associated with Shitan use?

Official regulatory guidance indicates that the use of this medicine is generally restricted to short-term treatment, typically not exceeding seven consecutive days. The specific effects or safety profile of extended, long-term use are not established through regulatory guidance.

Q: Does Shitan interact with commonly used over-the-counter pain relievers?

Official regulatory documents state that no clinically relevant unfavorable interactions have been reported when Shitan is taken alongside most medicines.

Q: Is it normal to feel a bit tired when first taking Shitan?

The adverse effects listed in official product information typically include neurological effects such as dizziness and headache. Tiredness or general fatigue are not commonly listed as a standalone side effect of the medicine.

Q: Is there a generic version of Shitan?

Shitan is a brand name for the active substance Bromhexine hydrochloride. Since regulatory documents confirm the active ingredient, this substance may be available globally under different trade designations.

Q: Does Shitan interact negatively with supplements like fish oil or multivitamins?

Official documentation generally notes the lack of clinically relevant unfavorable interactions with most substances. However, some regulatory guidance includes a statement about informing a healthcare provider regarding the use of nutritional supplements or herbal products.

Q: What research evidence supports the use of Shitan?

Official information describes the drug's mechanism as a secretolytic agent that chemically breaks down thick mucus. This action is clinically recognized for its role in improving secretion flow and enhancing the mucociliary clearance pathway.

Q: Can Shitan cause issues with sleep?

Based on the official list of adverse effects, insomnia or other specific sleep disturbances are not documented as a common side effect of the medicine.

Q: Is Shitan licensed in other countries besides the US?

Yes, this medication is licensed and its product information is regulated by authoritative bodies outside of the United States. Regulatory documents cited in the official material originate from agencies like the European Medicines Agency (EMA), the Therapeutic Goods Administration (TGA) of Australia, and Health Canada.

Q: Are there any known issues with taking Shitan and herbal remedies?

Official regulatory information notes that no clinically relevant unfavorable interactions have been reported with most medicines. However, some guidance includes a statement about informing a healthcare provider regarding the use of herbal products.

Q: Why is the drug 'Shitan' not recommended for people with [Specific Contraindication]?

Cautions are issued for individuals with a history of gastric ulceration because the drug may disrupt the protective mucosal barrier in the stomach. Restrictions are also noted for those with severe liver or kidney impairment due to the potential for the body to clear the substance less effectively.

Q: Does Shitan interact with birth control pills?

No specific interaction with birth control pills is explicitly documented in the official labeling. However, it is noted that Shitan may increase the concentration of certain antibiotics when taken at the same time.

Q: Is Shitan habit-forming or addictive?

Official drug documents do not classify the active substance in Shitan as a controlled substance. Regulatory documents indicate that the active substance is not classified as having a high abuse potential or risk of habit formation.

Q: Can Shitan affect my ability to drive or operate machinery?

Official product information states that, when the medicine is used as recommended and without the development of side effects, it is not known to have any effect on an individual’s ability to drive or operate machinery.

Q: Does Shitan have a 'Black Box Warning' from the FDA?

The active substance, Bromhexine hydrochloride, is not an approved drug product for human use by the US Food and Drug Administration (FDA). As a result, it does not carry an official Black Box Warning from that specific US regulatory agency.

Q: What is the shelf life of Shitan?

Official product labeling for the oral liquid formulation lists the shelf life as 3 Years. Regulatory guidance specifies that the medicine be kept in its original container and stored according to specific temperature and environmental protection guidelines.

Q: Can men and women use Shitan for the same reasons?

Regulatory guidelines for the medicine's indication and use are generally not differentiated based on sex. The official documents only specify use restrictions that apply to pregnant and breast-feeding women.

Q: What if I take Shitan but don't feel like it's working?

Official safety communications state that individuals with concerns about the effectiveness of the medicine or if their condition is not improving are typically advised to speak with a healthcare provider.

Q: Does Shitan require any special monitoring or blood tests?

Official documentation mentions that a transient rise in certain enzyme levels (serum aminotransferase values) has been reported in rare cases. However, mandatory routine blood tests or special monitoring are not typically specified in the patient-facing labeling.

Q: What should be done if I experience a serious side effect from Shitan?

Official safety communications describe the requirement to immediately stop treatment and contact a doctor if symptoms of a severe allergic reaction or progressive skin rash occur.

Q: Are there any restrictions on activity while using Shitan?

General restrictions on activity are not specified in the official labeling. However, information is provided that the medicine is not known to affect the ability to drive or operate machinery when used as recommended.

Q: What does official guidance say about Shitan and laboratory test interference?

Official documents describe the potential for transient elevated serum aminotransferase values. However, official guidance does not provide general patient information on specific interference with common laboratory tests.

Q: Can Shitan affect mood or mental state?

The documented adverse effects profile lists common neurological effects like headache and dizziness. It does not list adverse effects such as mood changes, depression, or hallucinations.

Q: What is the regulatory status of Shitan in terms of safety classification?

In Australia, the drug is officially classified by the Therapeutic Goods Administration (TGA) as a Pharmacy Medicine (Schedule 2). Furthermore, its Australian Pregnancy Category is listed as Category A.

The official labeling for Shitan (Bromhexine hydrochloride) defines precise requirements to ensure its stability.

Official Storage and Disposal Profile

Aspect	Regulatory Requirement
Temperature Requirements	Store the product at room temperature, typically at or below 25 C or 30 C (check specific label).
Environmental Protection	Keep the medicine protected from light, excessive warmth, and dampness.
Packaging Rules	Keep the medicine in its original container and ensure the container (e.g., syrup bottle) is tightly closed.
Child Safety	Keep out of the sight and reach of children and pets to prevent accidental ingestion.
Disposal Instructions	Unused or expired Shitan must not be flushed down the toilet or poured into a drain.
Disposal Preference	The best option is to use a drug take-back program. If unavailable, mix the medicine with an undesirable substance (like dirt) in a sealed bag before placing it in household trash.